Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston
Verrica Pharmaceuticals (Nasdaq: VRCA), a dermatology therapeutics company, has announced its participation in the TD Cowen 45th Annual Health Care Conference in Boston. Jayson Rieger, PhD, MBA, President and CEO, will engage in a fireside chat at the event.
The presentation is scheduled for Monday, March 3, 2025, at 2:30 pm ET in Boston, MA. Interested participants can access a live webcast through the provided link or via the Investors/Presentations & Events section on Verrica's website. The webcast recording will remain available for 90 days after the event.
Verrica Pharmaceuticals (Nasdaq: VRCA), un'azienda di terapia dermatologica, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen a Boston. Jayson Rieger, PhD, MBA, Presidente e CEO, parteciperà a una chiacchierata informale durante l'evento.
La presentazione è programmata per lunedì 3 marzo 2025, alle 14:30 ET a Boston, MA. I partecipanti interessati possono accedere a una trasmissione in diretta tramite il link fornito o attraverso la sezione Investitori/Presentazioni & Eventi sul sito web di Verrica. La registrazione della trasmissione rimarrà disponibile per 90 giorni dopo l'evento.
Verrica Pharmaceuticals (Nasdaq: VRCA), una empresa de terapias dermatológicas, ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen en Boston. Jayson Rieger, PhD, MBA, Presidente y CEO, participará en una charla informal durante el evento.
La presentación está programada para el lunes 3 de marzo de 2025, a las 2:30 pm ET en Boston, MA. Los participantes interesados pueden acceder a una transmisión en vivo a través del enlace proporcionado o en la sección de Inversores/Presentaciones y Eventos en el sitio web de Verrica. La grabación de la transmisión estará disponible durante 90 días después del evento.
베리카 제약 (Nasdaq: VRCA), 피부과 치료 회사가 보스턴에서 열리는 TD Cowen 제45회 연례 건강 관리 컨퍼런스에 참여한다고 발표했습니다. 제이슨 리거, PhD, MBA, 사장 겸 CEO가 이 행사에서 대화에 참여할 예정입니다.
발표는 2025년 3월 3일 월요일 오후 2시 30분 ET에 보스턴, MA에서 진행됩니다. 관심 있는 참가자는 제공된 링크를 통해 생중계에 접속하거나 Verrica 웹사이트의 투자자/프레젠테이션 및 이벤트 섹션을 통해 접속할 수 있습니다. 생중계 녹화는 행사 후 90일 동안 이용 가능합니다.
Verrica Pharmaceuticals (Nasdaq: VRCA), une entreprise de thérapies dermatologiques, a annoncé sa participation à la 45e Conférence Annuelle sur la Santé de TD Cowen à Boston. Jayson Rieger, PhD, MBA, Président et CEO, participera à une discussion informelle lors de l'événement.
La présentation est prévue pour le lundi 3 mars 2025, à 14h30 ET à Boston, MA. Les participants intéressés peuvent accéder à un webinaire en direct via le lien fourni ou via la section Investisseurs/Présentations & Événements sur le site Web de Verrica. L'enregistrement du webinaire restera disponible pendant 90 jours après l'événement.
Verrica Pharmaceuticals (Nasdaq: VRCA), ein Unternehmen für dermatologische Therapien, hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen in Boston angekündigt. Jayson Rieger, PhD, MBA, Präsident und CEO, wird an einer informellen Gesprächsrunde während der Veranstaltung teilnehmen.
Die Präsentation ist für Montag, den 3. März 2025, um 14:30 Uhr ET in Boston, MA, geplant. Interessierte Teilnehmer können über den bereitgestellten Link oder den Bereich Investoren/Präsentationen & Veranstaltungen auf der Website von Verrica auf einen Live-Stream zugreifen. Die Aufzeichnung des Live-Streams bleibt 90 Tage nach der Veranstaltung verfügbar.
- None.
- None.
WEST CHESTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston.
TD Cowen 45th Annual Health Care Conference, March 3-5, 2025
Event details:
Date: Monday, March 3, 2025
Time: 2:30 pm ET
Location: Boston, MA
Participants may access a live webcast of the event by clicking the link here.
The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH (VP-102) is also in development to treat common warts and external genital warts, two of the largest remaining unmet needs in medical dermatology. Verrica is developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
John J Kirby
Interim Chief Financial Officer
jkirby@verrica.com
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Chris Calabrese
LifeSci Advisors
ccalabrese@lifesciadvisors.com
FAQ
When is Verrica Pharmaceuticals (VRCA) presenting at the TD Cowen Healthcare Conference 2025?
How can investors watch Verrica's (VRCA) TD Cowen conference presentation?
How long will Verrica's (VRCA) TD Cowen conference presentation replay be available?
Who is representing Verrica Pharmaceuticals (VRCA) at the TD Cowen Healthcare Conference?
